Filing Details
- Accession Number:
- 0001127602-16-046101
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-03-11 16:05:07
- Reporting Period:
- 2016-03-09
- Filing Date:
- 2016-03-11
- Accepted Time:
- 2016-03-11 16:05:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
64803 | Cvs Health Corp | CVS | Retail-Drug Stores And Proprietary Stores (5912) | 050494040 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1194413 | J Larry Merlo | One Cvs Drive Woonsocket RI 02895- | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-03-09 | 38,247 | $36.23 | 261,287 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-03-09 | 38,247 | $100.00 | 223,040 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option | Disposition | 2016-03-09 | 38,247 | $0.00 | 38,247 | $36.23 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
114,741 | 2011-04-01 | 2017-04-01 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 353,291 | Indirect | By Trust As Beneficiary |
Common Stock (Restricted) | 240,095 | Direct | |
Esop Common Stock | 6,513 | Indirect | By ESOP |
Stock Unit | 563,191 | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Phantom Stock Credits | $1.00 | 5,131 | 5,131 | Direct | ||
Common Stock | Stock Option | $34.96 | 2012-04-01 | 2018-04-01 | 241,150 | 241,150 | Direct |
Common Stock | Stock Option | $45.07 | 2013-04-02 | 2019-04-02 | 332,736 | 332,736 | Direct |
Common Stock | Stock Option | $54.53 | 2014-04-01 | 2020-04-01 | 314,713 | 314,713 | Direct |
Common Stock | Stock Option | $74.29 | 2015-04-01 | 2021-04-01 | 335,697 | 335,697 | Direct |
Common Stock | Stock Option | $102.26 | 2016-04-01 | 2022-04-01 | 273,929 | 273,929 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
5,131 | 5,131 | Direct | |
2018-04-01 | 241,150 | 241,150 | Direct |
2019-04-02 | 332,736 | 332,736 | Direct |
2020-04-01 | 314,713 | 314,713 | Direct |
2021-04-01 | 335,697 | 335,697 | Direct |
2022-04-01 | 273,929 | 273,929 | Direct |
Footnotes
- All sales were effected pursuant to a Rule 10b5-1 plan.
- Option became exercisable in three equal annual installments, commencing 4/1/2011.
- Each share credit is equivalent to one share; 1-for-1 conversion.
- Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- Reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
- Option became exercisable in four equal annual installments, commencing 4/1/2012.
- Option became exercisable in four equal annual installments, commencing 4/2/2013.
- Option became exercisable in four equal annual installments, commencing 4/1/2014.
- Option became exercisable in four equal annual installments, commencing 4/1/2015.
- Option becomes exercisable in four equal annual installments, commencing 4/1/2016.